3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
2
Venous Thrombosis
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
ruxolitinib
21
Azacitidine
5
ponatinib
4
parsaclisib
4
nilotinib
4
itacitinib
4
anagrelide
3
Phlebotomy
3
Imatinib Mesylate
3
INCB039110
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
pemigatinib
2
luspatercept
2
imetelstat
2
givinostat hydrochloride
2
givinostat
2
fedratinib
2
asciminib
2
INCB057643
2
Gemcitabine
2
GRN163L peptide
2
spartalizumab
1
sonidegib
1
selinexor
1
sabatolimab
1
rucaparib
1
pembrolizumab
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myeloproliferative Disorders
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled